Acadia Pharmaceuticals (ACAD) Receivables (2016 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Receivables of $148.4 million for Q1 2026, up 30.49% year-over-year from $113.7 million in Q1 2025, and little changed quarter-over-quarter from $148.2 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) Receivables (2016 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Receivables history runs 11 years deep, the most recent figure standing at $148.4 million for Q1 2026.
- In Q1 2026, Receivables rose 30.49% year-over-year to $148.4 million; the TTM figure through Mar 2026 stood at $148.4 million (up 30.49% YoY), while the FY2025 annual figure was $148.2 million, up 41.58% from the prior year.
- Receivables for Q1 2026 stood at $148.4 million, roughly flat from $148.2 million in the prior quarter.
- The five-year high for Receivables was $148.4 million in Q1 2026, with the low at $56.1 million in Q3 2022.
- The 5-year median for Receivables is $102.4 million (2023), against an average of $99.9 million.
- The sharpest annual moves came in 2022 and 2023: Receivables fell 8.97% in 2022, then surged 68.4% in 2023.
- Acadia Pharmaceuticals' Receivables stood at $63.1 million in 2022, then soared by 62.25% to $102.4 million in 2023, then grew by 2.29% to $104.7 million in 2024, then jumped by 41.58% to $148.2 million in 2025, then gained by 0.1% to $148.4 million in 2026.
- Business Quant data shows ACAD's Receivables at $148.4 million in Q1 2026, $148.2 million in Q4 2025, and $139.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | 166.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 166.33 Mn |
| Mar 31, 2026 | 148.38 Mn |
| Dec 31, 2025 | 148.23 Mn |
| Sep 30, 2025 | 139.44 Mn |
| Jun 30, 2025 | 119.69 Mn |
| Mar 31, 2025 | 113.71 Mn |
| Dec 31, 2024 | 104.70 Mn |
| Sep 30, 2024 | 110.36 Mn |
| Jun 30, 2024 | 110.39 Mn |
| Mar 31, 2024 | 100.08 Mn |
| Dec 31, 2023 | 102.35 Mn |
| Sep 30, 2023 | 94.53 Mn |
| Jun 30, 2023 | 84.16 Mn |
| Mar 31, 2023 | 70.25 Mn |
| Dec 31, 2022 | 63.08 Mn |
| Sep 30, 2022 | 56.14 Mn |
| Jun 30, 2022 | 68.89 Mn |
| Mar 31, 2022 | 63.48 Mn |
| Dec 31, 2021 | 65.34 Mn |
| Sep 30, 2021 | 61.67 Mn |